Solid Phase Synthesis of PSMA Ligands for High Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing prostate-specific membrane antigen (PSMA) ligands, such as those with a glutamate-urea-lysine (GUL) moiety and chelating agents, are not cost-effective and do not efficiently produce high-purity quantities necessary for cancer treatment, particularly for prostate cancer therapy.
Innovation Solution
A method for synthesizing PSMA ligands using solid phase synthesis, involving specific steps with resin-based compounds and deprotecting agents, which allows for efficient and cost-effective production of compounds like PSMA-11 with yields greater than or equal to 40%, utilizing a linker and protecting groups to facilitate purification and handling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional liquid-phase synthesis methods are used for PSMA ligands, then the synthesis flexibility is maintained, but the production cost increases and yield decreases
Solution Approach 1:
The patent employs solid support (resin) as an intermediary carrier to anchor the growing PSMA ligand chain during synthesis. This solid-phase approach enables simplified purification through filtration and washing, eliminating complex liquid-liquid extraction steps, thereby reducing manufacturing costs and improving overall synthesis yield through minimal product loss.
Solution Approach 2:
The synthesis process is divided into discrete modular steps with protected amino acid building blocks that are sequentially added to the solid support. Each amino acid unit (Glu, Lys, urea linkages) is introduced as a separate protected intermediate, allowing systematic assembly and easy removal of excess reagents, which reduces costs and improves yield.
2Manufacturing precision
If multi-step synthesis with protecting groups is used to ensure purity, then the product purity increases, but the synthesis time and complexity increase
Solution Approach 1:
Protecting groups (Fmoc, Boc, tBu) are pre-installed on amino acid building blocks before they are added to the solid support. This preliminary protection prevents unwanted side reactions during coupling steps, ensuring high product purity without requiring additional purification steps that would extend synthesis time.
Solution Approach 2:
The solid-phase synthesis enables continuous sequential addition of protected amino acids to the growing chain on the resin. Multiple coupling and deprotection cycles can be performed in succession without isolating intermediates, maintaining continuous productive action while ensuring purity through the protective groups that prevent side reactions throughout the process.
3Productivity
If solid phase synthesis is used to improve yield and reduce cost, then the production efficiency increases, but the device complexity and purification steps increase
Solution Approach 1:
The solid support resin serves a dual function: it acts as both the growing substrate for the PSMA ligand and as a built-in purification filter. Excess reagents and byproducts automatically remain in solution and are removed by simple filtration, while the desired product remains bound to the resin until final cleavage. This self-service capability eliminates the need for complex purification apparatus while maintaining high production efficiency.
Data Source
AI summary
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal.